Page 40 - GALENIKA MEDICAL JOURNAL

Literatura 23. Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling
LR, et al. Efficacy and Safety of Bempedoic Acid in Patients With
Hypercholesterolemia and Statin Intolerance. J Am Heart Assoc. 2019
1. Cardiovascular Diseases. Available online: https://www.who.int/health- Apr 2;8(7):e011662.
topics/cardiovascular-diseases (accessed on 24 December 2023). 24. Poznyak AV, Sukhorukov VN, Eremin II, Nadelyaeva II, Gutyrchik NA,
2. Teo KK, Rafiq T. Cardiovascular Risk Factors and Prevention: Orekhov AN. Proprotein Convertase Subtilisin/Kexin 9 as a Modifier
A Perspective From Developing Countries. Can J Cardiol. 2021 of Lipid Metabolism in Atherosclerosis. Biomedicines. 2023 Feb
May;37(5):733-43. 9;11(2):503.
3. Berberich AJ, Hegele RA. A Modern Approach to Dyslipidemia. Endocr 25. Sindi AAA. Genetics, Safety, Cost-Effectiveness, and Accessibility of
Rev. 2022 Jul 13;43(4):611-53. Injectable Lipid-Lowering Agents: A Narrative Review. J Lipids. 2023 Mar
8;2023:2025490.
4. Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt
Ms et al. Heart Disease and Stroke Statistics-2022 Update: A 26. Kim K, Ginsberg HN, Choi SH. New, Novel Lipid-Lowering Agents for
Report From the American Heart Association. Circulation. 2022 Feb Reducing Cardiovascular Risk: Beyond Statins. Diabetes Metab J. 2022
22;145(8):e153-e639. Jul;46(4):517-32.
5. Thongtang N, Sukmawan R, Llanes EJB, Lee ZV. Dyslipidemia 27. Mohamed F, Mansfield B, Raal FJ. Targeting PCSK9 and Beyond for the
management for primary prevention of cardiovascular events: Best Management of Low-Density Lipoprotein Cholesterol. J Clin Med. 2023
in-clinic practices. Prev Med Rep. 2022 May 5;27:101819. Aug 2;12(15):5082.
6. Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global 28. Yang J, Ma X, Niu D, Sun Y, Chai X, Deng Y, et al. PCSK9 inhibitors
epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021 Oct;18(10):689- suppress oxidative stress and inflammation in atherosclerotic
700. development by promoting macrophage autophagy. Am J Transl Res.
2023 Aug 15;15(8):5129-44.
7. Yanai H, Yoshida H. Secondary dyslipidemia: its treatments and
association with atherosclerosis. Glob Health Med. 2021 Feb 28;3(1):15- 29. Tokgözoğlu L, Libby P. The dawn of a new era of targeted lipid-lowering
23. therapies. Eur Heart J. 2022 Sep 7;43(34):3198-208.
8. Aygun S, Tokgozoglu L. Comparison of Current International 30. Wołowiec Ł, Osiak J, Wołowiec A, Wijata A, Grześk E, Kozakiewicz M,
Guidelines for the Management of Dyslipidemia. J Clin Med. 2022 Dec et al. Inclisiran-Safety and Effectiveness of Small Interfering RNA in
6;11(23):7249. Inhibition of PCSK-9. Pharmaceutics. 2023 Jan 18;15(2):323.
9. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon 31. Ray KK, Troquay RPT, Visseren FLJ, Leiter LA, Scott Wright R,
L, et al; ESC Scientific Document Group. 2019 ESC/EAS Guidelines Vikarunnessa S, et al. Long-term efficacy and safety of inclisiran in
for the management of dyslipidaemias: lipid modification to reduce patients with high cardiovascular risk and elevated LDL cholesterol
cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-88. (ORION-3): results from the 4-year open-label extension of the ORION-1
trial. Lancet Diabetes Endocrinol. 2023 Feb;11(2):109-19.
10. Alonso R, Argüeso R, Álvarez-Baños P, Muñiz-Grijalvo O, Diaz-Diaz JL,
Mata P. Familial Hypercholesterolemia and Lipoprotein(a): Two Partners 32. Mason RP, Libby P, Bhatt DL. Emerging Mechanisms of Cardiovascular
in Crime? Curr Atheroscler Rep. 2022 Jun;24(6):427-34. Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid.
Arterioscler Thromb Vasc Biol. 2020 May;40(5):1135-47.
11. Averna M, Stroes E; lipid alterations beyond LDL expert working group.
How to assess and manage cardiovascular risk associated with lipid 33. Khan SU, Lone AN, Khan MS, Virani SS, Blumenthal RS, Nasir K, et al.
alterations beyond LDL. Atheroscler Suppl. 2017 Apr;26:16-24. Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic
review and meta-analysis. EClinicalMedicine. 2021 Jul 8;38:100997.
12. Lalić K, Rajković N, Popović L, Lukač SS, Stošić L, Rasulić I, et al. The
effects of 3-year statin therapy and the achievement of LDL cholesterol 34. Kim NH, Kim SG. Fibrates Revisited: Potential Role in Cardiovascular
target values in familial hypercholesterolemia patients: An experience Risk Reduction. Diabetes Metab J. 2020 Apr;44(2):213-21.
from Serbia. Atherosclerosis. 2018 Oct;277:298-303. 35. Kim KA, Kim NJ, Choo EH. The Effect of Fibrates on Lowering Low-
13. Ray KK, Ginsberg HN, Davidson MH, Pordy R, Bessac L, Minini P, et al. Density Lipoprotein Cholesterol and Cardiovascular Risk Reduction:
Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Systemic Review and Meta-analysis. Eur J Prev Cardiol. 2023 Oct
A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With 19:zwad331.
Control. Circulation. 2016 Dec 13;134(24):1931-43. 36. Tikka A, Jauhiainen M. The role of ANGPTL3 in controlling lipoprotein
14. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et metabolism. Endocrine. 2016 May;52(2):187-93.
al. Interpretation of the evidence for the efficacy and safety of statin 37. Kosmas CE, Bousvarou MD, Sourlas A, Papakonstantinou EJ,
therapy. Lancet. 2016 Nov 19;388(10059):2532-61. Peña Genao E, Echavarria Uceta R, et al. Angiopoietin-Like
15. Masson W, Lobo M, Siniawski D, Molinero G, Masson G, Huerín M, et Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory
al. Role of non-statin lipid-lowering therapy in coronary atherosclerosis Hypercholesterolemia. Clin Pharmacol. 2022 Jul 16;14:49-59.
regression: a meta-analysis and meta-regression. Lipids Health Dis. 38. Rosenson RS, Burgess LJ, Ebenbichler CF, Baum SJ, Stroes ESG, Ali S,
2020 May 27;19(1):111.
et al. Longer-Term Efficacy and Safety of Evinacumab in Patients With
16. Michaeli DT, Michaeli JC, Albers S, Boch T, Michaeli T. Established Refractory Hypercholesterolemia. JAMA Cardiol. 2023 Nov 1;8(11):1070-
and Emerging Lipid-Lowering Drugs for Primary and Secondary 6.
Cardiovascular Prevention. Am J Cardiovasc Drugs. 2023 Sep;23(5):477- 39. Gareri C, Polimeni A, Giordano S, Tammè L, Curcio A, Indolfi C.
95. Antisense Oligonucleotides and Small Interfering RNA for the
17. Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ. Effect of statins Treatment of Dyslipidemias. J Clin Med. 2022 Jul 4;11(13):3884.
on HDL-C: a complex process unrelated to changes in LDL-C: analysis of 40. Calcaterra I, Lupoli R, Di Minno A, Di Minno MND. Volanesorsen to
the VOYAGER Database. J Lipid Res. 2010 Jun;51(6):1546-53. treat severe hypertriglyceridaemia: A pooled analysis of randomized
18. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, controlled trials. Eur J Clin Invest. 2022 Nov;52(11):e13841.
Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and 41. Merćep I, Strikić D, Slišković AM, Reiner Ž. New Therapeutic Approaches
drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
in Treatment of Dyslipidaemia-A Narrative Review. Pharmaceuticals
19. Pandor A, Ara RM, Tumur I, Wilkinson AJ, Paisley S, Duenas A, et al. (Basel). 2022 Jul 7;15(7):839.
Ezetimibe monotherapy for cholesterol lowering in 2,722 people: 42. Gouni-Berthold I, Schwarz J, Berthold HK. Updates in Drug Treatment
systematic review and meta-analysis of randomized controlled trials. J of Severe Hypertriglyceridemia. Curr Atheroscler Rep. 2023
Intern Med. 2009 May;265(5):568-80. Oct;25(10):701-9.
20. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et 43. Yeang C, Karwatowska-Prokopczuk E, Su F, Dinh B, Xia S, Witztum JL,
al. IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after et al. Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected
Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18;372(25):2387-97. Low-Density Lipoprotein Cholesterol. J Am Coll Cardiol. 2022 Mar
21. Bilen O, Ballantyne CM. Bempedoic Acid (ETC-1002): an Investigational 22;79(11):1035-46.
Inhibitor of ATP Citrate Lyase. Curr Atheroscler Rep. 2016 Oct;18(10):61.
44. O'Donoghue ML, Rosenson RS, Gencer B, López JAG, Lepor NE, Baum
22. Banach M, Penson PE, Farnier M, Fras Z, Latkovskis G, Laufs U, SJ, et al. OCEAN(a)-DOSE Trial Investigators. Small Interfering RNA to
et al. Bempedoic acid in the management of lipid disorders and Reduce Lipoprotein(a) in Cardiovascular Disease. N Engl J Med. 2022
cardiovascular risk. 2023 position paper of the International Lipid Nov 17;387(20):1855-64.
Expert Panel (ILEP). Prog Cardiovasc Dis. 2023 Jul-Aug;79:2-11.

38 DOI: 10.5937/Galmed2409031L